Is ketamine safe? Risks, side effects, and who should avoid it

Ketamine has a reputation for being either dangerous or miracle-safe, depending on who is talking. The accurate version sits in between: in monitored clinical settings, ketamine-based treatment is generally well tolerated, but it carries labeled risks that patients should understand before consenting to anything.

The boxed warnings

The FDA label for SPRAVATO® (esketamine) — the only ketamine-based psychiatric medicine — carries boxed warnings for sedation, dissociation, respiratory depression, abuse and misuse, and suicidal thoughts and behaviors 1. Off-label IV, IM, and oral ketamine share these pharmacological risks. What the boxed warnings translate to in practice:

• Monitoring. Every legitimate protocol observes patients for at least two hours after esketamine dosing, and continuously during an IV infusion, because sedation and blood-pressure spikes can occur.
• Abuse potential. Ketamine is a controlled substance with genuine misuse potential. Repeated unsupervised use is exactly what the REMS program for esketamine exists to prevent — and a reason our clinic vetting guide tells you to ask about screening and take-home policies.
• Suicidal thoughts and behaviors. The label warns of increased suicidal thoughts in young people on antidepressants generally; it also states that esketamine's effectiveness in preventing suicide has not been demonstrated 1. Ketamine treatment is not a crisis intervention. If you are in crisis, call or text 988 for the Suicide & Crisis Lifeline.

Common short-term side effects

Most are transient and resolve within hours: dissociation (the floating, detached sensation), dizziness, nausea, elevated blood pressure during and shortly after dosing, blurred vision, and fatigue. Some clinics pre-treat nausea. The dissociative effect is why you cannot drive after a session — see what a first infusion is like.

Longer-term concerns

The most documented longer-term issue with repeated frequent use is ketamine-induced cystitis — bladder inflammation, pain, and urinary frequency — seen chiefly in heavy recreational use but a real consideration for any frequent-dosing protocol, including oral ketamine taken at home [editorial interpretation]. Cognitive effects with heavy long-term use are an open research question. This is one reason our oral ketamine at home article is more cautious than most clinic marketing.

Who should not get ketamine treatment (or needs medical clearance)

Clinics commonly screen out or require clearance for:

• Uncontrolled hypertension or certain cardiovascular conditions — ketamine raises blood pressure
• A history of psychosis — dissociative anesthetics can worsen psychotic disorders
• Active substance misuse — both a safety issue and, for ketamine itself, an abuse risk
• Pregnancy — safety has not been established
• Certain liver conditions — with repeated dosing

This list is a common clinical pattern, editorially compiled — not a personal medical determination. A prescriber who knows your full history makes that call, which is why screening quality is a core item in how to vet a clinic.

The supervision rule that has no exceptions

Every route — IV, IM, oral, nasal — carries the same core risks, which is why no ketamine-based treatment is self-administered without supervision. SPRAVATO® enforces this through its REMS program 1; IV clinics enforce it through their own protocols. The difference is the difference between a controlled treatment and misuse, and it is the single most important safety fact on this site. Our complete 2026 ketamine guide covers the landscape; our condition guides separate evidence from hype per condition.

Sources

1. FDA Prescribing Information for SPRAVATO® (esketamine), revised January 2025: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/211243s016lbl.pdf. Side-effect and screening patterns outside the label are editorial interpretation based on publicly reported clinical practice.